Heme Themes: Challenges in averting the progression of MPN, MDS

ALEXANDRIA, VA. – What are the emerging combination therapies for slowing disease progression and improving therapeutic tolerability in myeloproliferative neoplasms and myelodysplastic syndromes?

Join Dr. Jaroslaw Maciejewski, chairman of the department of translational hematology and oncology research at the Taussig Cancer Institute, Cleveland Clinic, and professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Dr. Ruben A. Mesa, chair of the Division of Hematology/Oncology, department of internal medicine, Mayo Clinic, Scottsdale, Arizona, for their one-on-one discussion of emerging treatment approaches. Then join the conversation by posting your comments and recommendations for other Heme Themes.

[email protected]

ALEXANDRIA, VA. – What are the emerging combination therapies for slowing disease progression and improving therapeutic tolerability in myeloproliferative neoplasms and myelodysplastic syndromes?

Join Dr. Jaroslaw Maciejewski, chairman of the department of translational hematology and oncology research at the Taussig Cancer Institute, Cleveland Clinic, and professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Dr. Ruben A. Mesa, chair of the Division of Hematology/Oncology, department of internal medicine, Mayo Clinic, Scottsdale, Arizona, for their one-on-one discussion of emerging treatment approaches. Then join the conversation by posting your comments and recommendations for other Heme Themes.

[email protected]

ALEXANDRIA, VA. – What are the emerging combination therapies for slowing disease progression and improving therapeutic tolerability in myeloproliferative neoplasms and myelodysplastic syndromes?

Join Dr. Jaroslaw Maciejewski, chairman of the department of translational hematology and oncology research at the Taussig Cancer Institute, Cleveland Clinic, and professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Dr. Ruben A. Mesa, chair of the Division of Hematology/Oncology, department of internal medicine, Mayo Clinic, Scottsdale, Arizona, for their one-on-one discussion of emerging treatment approaches. Then join the conversation by posting your comments and recommendations for other Heme Themes.

[email protected]